Fabry disease is a rare inherited disorder in which the body cannot produce enough of an enzyme called alpha-galactosidase A, leading to a buildup of fatty substances in cells throughout the body. Over time, this accumulation damages the kidneys, heart, brain, and nervous system. Because the gene responsible sits on the X chromosome, Fabry disease was long considered a condition that only seriously affected males, but research over the past two decades has overturned that assumption: roughly 70% of female carriers develop symptoms, and some experience organ damage just as severe as their male counterparts.1PubMed Central. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis
What Goes Wrong at the Cellular Level
The enzyme that is deficient in Fabry disease, alpha-galactosidase A, normally breaks down a type of fat molecule called globotriaosylceramide (usually shortened to Gb3 or GL-3). When the enzyme is missing or barely active, Gb3 and a related molecule called lyso-Gb3 pile up inside cells, especially in the walls of blood vessels, in kidney cells, in the heart, and in nerve fibers.2PubMed. Fabry disease: a review The buildup is progressive. In classic Fabry disease, it begins before birth and accumulates throughout life. Plasma lyso-Gb3 levels are markedly higher in males with the classic form than in those with milder variant forms, and even in females the level of lyso-Gb3 tracks inversely with how much enzyme activity they retain.3Molecular Genetics and Metabolism. Plasma globotriaosylsphingosine as a biomarker of Fabry disease
Why Women Are Not Just “Carriers”
Because the gene for alpha-galactosidase A (called GLA) sits on the X chromosome, and males have only one X, a single mutated copy is enough to cause severe disease. Women have two X chromosomes, so they carry one working copy and one mutated copy. For decades, this led clinicians to assume women would be protected. The reality is more complicated. In each cell of a woman’s body, one X chromosome is randomly switched off early in development. If the X carrying the healthy gene is silenced in a large proportion of cells in a given organ, that organ may function almost as poorly as it would in an affected male.4PubMed. Female Fabry disease patients and X-chromosome inactivation
This randomness explains the wide range of disease severity in women: some remain virtually symptom-free their entire lives, while others develop the full spectrum of cardiac, kidney, and cerebrovascular problems seen in men. The outdated idea that females are “just carriers” has contributed to delayed diagnoses and under-treatment for many women with the disease.
Early Warning Signs
Fabry disease often announces itself in childhood, but because the symptoms overlap with common conditions, years can pass before the correct diagnosis is made. The earliest and most frequent complaint is pain, particularly burning or tingling in the hands and feet that can be triggered by heat, exercise, or fever. Most patients experience this pain beginning in early childhood, and it is thought to stem from damage to small nerve fibers, although the exact molecular mechanisms remain poorly understood.5Rare Disease and Orphan Drugs Journal. Neuropathy and pain in Fabry disease
Two visible signs are especially helpful for diagnosis. Angiokeratomas are clusters of small, dark-red raised spots that tend to appear between the navel and the knees, often in a “bathing trunk” distribution. They are not dangerous on their own, but they are highly suggestive of Fabry disease when combined with other symptoms.6PubMed. Fabry disease: a review The second is cornea verticillata, a whorl-like pattern of deposits visible in the cornea during a slit-lamp eye exam. These deposits do not impair vision, but an ophthalmologist who recognizes the pattern can be the first clinician to suspect Fabry disease.7PubMed. Cornea verticillata – a clinical marker of Fabry disease: case report In one study, the presence of cornea verticillata and acral pain together efficiently separated patient clusters by disease severity.8PLOS ONE. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease
Gastrointestinal problems are another early and frequently overlooked feature. Many patients report cramping, diarrhea, nausea, or early fullness after eating, all thought to result from nerve and muscle changes in the gut wall that impair normal motility. Because these symptoms mimic irritable bowel syndrome and other common digestive complaints, they rarely prompt a workup for a rare metabolic disease.9PubMed Central. Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis
Kidney Damage
The kidney is one of the organs most vulnerable to Gb3 accumulation. Podocytes, the specialized cells that form part of the kidney’s filtration barrier, are a primary target. As Gb3 builds up inside podocytes over time, these cells become injured and eventually die. Research using kidney biopsies from young Fabry patients has shown that podocyte Gb3 accumulation increases progressively with age, accompanied by widening of the cell’s foot processes, a structural marker of stress. Foot process widening correlates directly with the amount of protein spilling into the urine, which is itself a strong predictor of worsening kidney function.10PubMed Central. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease
Further work has demonstrated that Gb3 accumulation within podocytes rises until roughly age 27, beyond which the cells may simply not survive the burden. As podocytes are lost, the remaining cells cannot compensate indefinitely, and kidney function declines. The relationship between increasing podocyte Gb3, worsening structural damage, rising protein in the urine, and falling filtration rate has been well characterized and marks Fabry nephropathy as a hereditary metabolic podocytopathy.11PubMed Central. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss 12PubMed Central. The role of podocyte injury in the pathogenesis of Fabry disease nephropathy Without treatment, many patients with classic Fabry disease reach end-stage kidney failure by their thirties or forties.
Heart Disease in Fabry Patients
Cardiovascular involvement is the leading cause of death in Fabry disease. Gb3 deposits in cardiac tissue drive a cascade that includes thickening of the left ventricle, stiffening of the heart muscle, fibrosis, and, eventually, heart failure. Arrhythmias are common and contribute to both reduced quality of life and sudden death risk.13PubMed. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week 14PubMed Central. Fabry disease cardiomyopathy: A state-of-the-art review
In some patients, particularly those with later-onset variant forms, the heart is the first and sometimes the only organ to show obvious damage. These individuals may be diagnosed only after they present with unexplained left ventricular hypertrophy (thickening of the heart wall) at a cardiology clinic. Screening patients who have unexplained left ventricular hypertrophy has revealed that Fabry disease is more prevalent than originally thought, but it also creates a diagnostic gray zone: some patients turn out to carry genetic variants of unknown significance in the GLA gene, where it is unclear whether the variant truly causes disease or is a benign variant that coincidentally exists alongside cardiac hypertrophy from another cause. Misdiagnosis in either direction, missing Fabry disease or falsely labeling someone with it, carries consequences for the patient and their family.15PubMed. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance
Stroke at a Young Age
Fabry disease raises the risk of stroke, often decades earlier than it would normally occur. In a large registry analysis, about 7% of males and 4% of females with Fabry disease had experienced a stroke. The median age at first stroke was 39 in men and about 46 in women, and 30 patients had their first stroke before age 30. The vast majority were ischemic strokes, though a meaningful minority were hemorrhagic, particularly among males.16PubMed. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry A sobering finding from the same data was that many strokes occurred before patients had even been diagnosed with Fabry disease, and in some cases before any other clinical events had raised suspicion.17PubMed Central. Stroke and Fabry Disease: A Review of Literature This makes the case that young stroke patients without conventional risk factors should be screened for Fabry disease.
Getting to a Diagnosis
The average delay between first symptoms and a confirmed Fabry diagnosis has historically been many years. Children with burning pain in their hands and feet get told they have growing pains. Teenagers with GI problems get labeled with irritable bowel syndrome. Adults with unexplained kidney or heart disease may cycle through specialists before anyone thinks of a rare metabolic disorder. Expert panels have stressed the importance of reducing this diagnostic gap, since early treatment can alter the disease’s trajectory.18PubMed. Fabry disease revisited: Management and treatment recommendations for adult patients
For males, measuring the activity of alpha-galactosidase A in the blood is usually sufficient to establish a diagnosis, because affected males have very low or absent enzyme activity. For females, enzyme activity can fall anywhere from normal to very low depending on X-inactivation patterns, so a normal enzyme level does not rule out the disease. Genetic testing of the GLA gene is essential to confirm the diagnosis in women. A biomarker called lyso-Gb3 in plasma helps support the diagnosis and is elevated in most affected males, but a systematic review found that it can miss females with late-onset forms of the disease when used alone.19PubMed. The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review Combining enzyme activity measurement, lyso-Gb3 testing, and genetic sequencing together gives the most reliable results, particularly in females.20PubMed. Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing
Newborn Screening and the Female Diagnostic Gap
Newborn screening programs for Fabry disease have been piloted in more than 20 countries, and the data suggest that the disease is more prevalent than the traditional estimate of 1 in 40,000 males, largely because many mild or later-onset cases were previously unrecognized. A complicating factor is the high number of genetic variants of unknown significance that screening identifies, which can make it difficult to determine whether a newborn actually has or will develop the disease.21PubMed Central. Newborn Screening in Fabry Disease
A significant limitation of current newborn screening is that it reliably identifies only males. Data from Tennessee’s screening program between 2017 and 2024 illustrate the problem starkly: 25 males were identified through newborn screening, but zero females. In a broader database, the sex distribution was nearly equal (42 males and 39 females), confirming that females with Fabry disease exist in comparable numbers but are missed by screening. A third of the females diagnosed in that cohort were found only through cascade testing after their sons were picked up by newborn screening, at a median age of 28 years.22PubMed Central. Sex-Specific Diagnostic Inequality in Fabry Disease: Lessons Learned from Analysis of Newborn Screening and Cascade Testing in Tennessee from 2017 to 2024 This means newborn screening programs need to be paired with systematic family testing to avoid leaving an entire generation of affected women undiagnosed.
Treatment With Enzyme Replacement Therapy
The mainstay of Fabry disease treatment since the early 2000s has been enzyme replacement therapy, in which a manufactured version of the missing enzyme is infused intravenously every two weeks. Two forms have been available for years, agalsidase alfa and agalsidase beta, and a third, pegunigalsidase alfa (a longer-acting version), has been added more recently.23PubMed Central. Fabry Disease Therapy: State-of-the-Art and Current Challenges These infusions can reduce Gb3 accumulation, relieve some symptoms, and slow organ damage, but they work best when started early, before irreversible fibrosis has set in.
Head-to-head comparisons between the two older forms suggest some differences. An international cohort study found that agalsidase beta produced a more robust decrease in plasma lyso-Gb3, particularly in men with classic disease, and was associated with a higher proportion of patients showing a decrease in heart wall thickness during the first year of treatment. However, patients treated with agalsidase beta were also about 2.8 times more likely to develop anti-drug antibodies. The rate of kidney function decline was similar between the two forms.24Journal of Medical Genetics. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
Anti-drug antibodies are a significant unresolved challenge with enzyme replacement. The immune system of a male patient who produces no natural enzyme at all may recognize the infused enzyme as foreign and mount an antibody response. Neutralizing antibodies that block the enzyme’s activity are found in roughly 40% of treated males and have shown cross-reactivity between both agalsidase alfa and agalsidase beta. These antibodies can reduce or even negate the clinical benefit of treatment and sometimes cause infusion reactions.25PubMed Central. Current status of the immunogenicity of enzyme replacement therapy in fabry disease The optimal dose, best time to start, and how to manage patients who develop neutralizing antibodies remain open questions.
Oral Chaperone Therapy
Not all Fabry patients need intravenous infusions. For those whose genetic mutation produces an enzyme that is made but folds incorrectly and gets degraded before it can reach the cell’s recycling compartment, an oral drug called migalastat offers an alternative. Migalastat is a pharmacological chaperone: it binds to the misfolded enzyme, stabilizes its shape, and helps it reach the part of the cell where it needs to work.26PubMed Central. Chaperone Therapy in Fabry Disease The catch is that migalastat only works for patients with “amenable” mutations, meaning those that produce a structurally rescuable enzyme. Each patient’s specific mutation must be tested in vitro to confirm amenability. For patients with mutations that produce no enzyme at all, chaperone therapy has nothing to chaperone, and enzyme replacement remains necessary.
Gene Therapy and Substrate Reduction
The limitations of lifelong infusions and the restricted eligibility for chaperone therapy have pushed research toward more definitive approaches. Gene therapy aims to deliver a functional copy of the GLA gene to the patient’s own cells so they can produce the missing enzyme on their own. Multiple strategies are in development, using both in vivo delivery (where a viral vector carries the gene directly into the body, typically targeting the liver) and ex vivo methods (where cells are modified outside the body and then returned).27PubMed Central. Current and Investigational Therapeutics for Fabry Disease
Preclinical results have been encouraging. In a mouse model of Fabry disease, a single dose of a liver-directed gene therapy vector produced sustained enzyme activity in the bloodstream for at least six months. At the highest doses, enzyme activity reached more than 25 times normal wild-type levels, and the toxic substrates Gb3 and lyso-Gb3 were cleared to below 20% of untreated levels in the heart, kidney, liver, and plasma.28PubMed Central. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction A clinical lead vector derived from this work, designated ST-920, has moved into human trials. How well the results in mice translate to people, and whether a single infusion can provide lasting benefit measured in years rather than months, are the central questions these trials will answer.
Substrate reduction therapy takes the opposite approach: instead of replacing the enzyme or fixing the gene, it partially blocks the production of Gb3 in the first place. An oral inhibitor of the enzyme that synthesizes Gb3 could reduce the amount of material that accumulates, lowering the burden on whatever residual enzyme activity the patient has. This strategy is still investigational for Fabry disease, though the concept is already used in a related condition, Gaucher disease.29PubMed Central. Current and Investigational Therapeutics for Fabry Disease
Living With Fabry Disease
Beyond the organ-level damage that dominates medical discussions, Fabry disease takes a substantial toll on daily life. A cross-sectional study of 86 adults with the disease found that pain, physical limitations, difficulty managing everyday tasks, and psychiatric symptoms all weighed heavily on general health and functioning.30PubMed Central. Quality of life in patients with Fabry’s disease: a cross-sectional study of 86 adults Chronic pain that began in childhood, heat intolerance that limits outdoor activity, and unpredictable GI symptoms can make school, work, and social participation difficult long before any organ shows measurable decline on a lab test.
Management guidelines emphasize a personalized, multidisciplinary approach. A single Fabry patient may need a nephrologist monitoring kidney function, a cardiologist tracking heart wall thickness and rhythm, a neurologist managing pain, a gastroenterologist addressing motility problems, and a geneticist coordinating family screening. Adjunctive treatments, such as medications for nerve pain, blood pressure drugs to protect the kidneys, anticoagulants to reduce stroke risk, and cardiac interventions for arrhythmias, run alongside whatever disease-specific therapy the patient is on.31PubMed. Fabry disease revisited: Management and treatment recommendations for adult patients The disease is lifelong, and the treatment burden is real: biweekly infusions, frequent blood draws, periodic imaging, and the psychological weight of a progressive genetic diagnosis that may also affect your children. Understanding the full scope of the disease, not just the enzymology, matters for anyone navigating it.